Spots Global Cancer Trial Database for A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Official Title: A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Study ID: NCT03833180
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope ( Site 0010), Duarte, California, United States
University of California - San Diego ( Site 0003), La Jolla, California, United States
UCLA Hematology & Oncology ( Site 0007), Los Angeles, California, United States
University of Nebraska Medical Center ( Site 0006), Omaha, Nebraska, United States
Northwell Health ( Site 0009), New Hyde Park, New York, United States
Weill Cornell Medical College ( Site 0005), New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0014), New York, New York, United States
University of Rochester ( Site 0008), Rochester, New York, United States
Memorial Sloan-Kettering Cancer Center ( Site 0019), Uniondale, New York, United States
Oregon Health & Science University ( Site 0004), Portland, Oregon, United States
MD Anderson Cancer Center ( Site 0001), Houston, Texas, United States
MD Anderson Cancer Center ( Site 0011), Houston, Texas, United States
University of Virginia Cancer Center ( Site 0012), Charlottesville, Virginia, United States
Swedish Medical Center ( Site 0002), Seattle, Washington, United States
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
